Core Viewpoint - Deshi Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1] Company Overview - The company focuses on developing medical imaging products and services, with a product portfolio that includes six medical imaging software (including the core product AI AutoVision® and commercial product AutoVision®), three commercial medical devices, and four main reagent consumables [1] Key Product Information - The core product AI AutoVision® is a chromosome karyotype auxiliary diagnostic software that utilizes AI functionalities for intelligent analysis in prenatal diagnosis of birth defects and assisted reproductive diagnosis, demonstrating high sensitivity and specificity in multi-center clinical trials (e.g., sensitivity of 100.00% for detecting abnormal numbers, specificity of 100.00%) [1] Market Outlook - The intelligent medical imaging detection market is projected to grow significantly, with the global market expected to increase from $1.6 billion in 2024 to $25.1 billion by 2035, and the Chinese market anticipated to grow from RMB 2.4 billion in 2024 to RMB 78.1 billion by 2035, indicating a rapid growth trend [1]

Company Overview - Deshi Bio is a medical device company focused on developing medical imaging products and services, with a diverse product portfolio aimed at enhancing diagnostic efficiency and service quality [3][5] - The core product, AI AutoVision, is designed for chromosome karyotype analysis, providing timely notifications to doctors regarding chromosomal abnormalities [3][5] Product Pipeline - The company has developed six medical imaging software products, three commercialized medical devices, and four main reagents and consumables [3][5] - AI AutoVision has achieved 100% sensitivity and specificity in detecting numerical abnormalities and 94.05% sensitivity with 100% specificity for structural abnormalities [3][5] Financial Performance - For the fiscal year 2023, the company reported revenues of approximately RMB 52.84 million, with a gross profit of RMB 37.49 million [6][9] - The company recorded a net loss of RMB 56.12 million for the fiscal year 2023 [8] Market Overview - The global smart medical imaging detection market is projected to grow from USD 400 million in 2019 to USD 1.6 billion by 2024, with a compound annual growth rate (CAGR) of 34.6% [10] - In China, the market is expected to expand from RMB 100 million in 2019 to RMB 2.4 billion by 2024, with a CAGR of 80.3% [13] Board of Directors - The board consists of eight members, including two executive directors, three non-executive directors, and three independent non-executive directors, responsible for managing and operating the group's business [16]

Company Overview - Deshi Biotechnology Co., Ltd. focuses on developing medical imaging products and services, with a diverse product portfolio aimed at enhancing diagnostic efficiency and service quality [3][4] - The core product, AI AutoVision, is designed for chromosome karyotype analysis, supporting prenatal diagnosis of birth defects and assisted reproductive diagnosis [3][4] Product Pipeline - The company has developed six medical imaging software products, three commercialized medical devices, and four main reagents and consumables [3][5] - AI AutoVision has achieved 100% sensitivity and specificity in detecting numerical abnormalities and 94.05% sensitivity with 100% specificity for structural abnormalities [3][5] Financial Performance - For the fiscal year 2023, the company reported revenues of approximately RMB 52.84 million, with a gross profit of RMB 37.50 million [8][10] - The company recorded a net loss of RMB 56.12 million for the same period [9] Market Overview - The global smart medical imaging detection market is projected to grow from USD 400 million in 2019 to USD 1.6 billion by 2024, with a compound annual growth rate (CAGR) of 34.6% [11] - In China, the market is expected to expand from RMB 100 million in 2019 to RMB 2.4 billion by 2024, with a CAGR of 80.3% [14] Shareholding Structure - As of the latest available date, the major shareholders include Dr. Song, who holds approximately 30.04% of the shares, and several investment platforms managed by him, collectively controlling about 52.06% of the voting rights [19][21]